Kyowa Kirin Divests China Unit and Reduces Small-Molecule Discovery Efforts

Divestment of China Unit::
Kyowa Kirin is selling its China business to Hong Kong WinHealth Pharma Group Co. for ¥15 billion ($100 million).

Restructuring and Growth Strategy::
The divestment is part of Kyowa Kirin's broader strategy to restructure its operations in the Asia Pacific region to drive growth.

Reduction in Small-Molecule Discovery::
Kyowa Kirin is scaling back its small-molecule drug discovery activities as part of its global operational retooling.

Manufacturing and Research Cuts::
The company plans to reduce certain manufacturing roles and significantly cut back on small-molecule drug research activities.

Marketing Partnership::
Kyowa Kirin has also entered into a deal with DKSH Holding Ltd to market its drugs in other parts of the Asia Pacific region.